The DOI matches its Crossref record.
Longitudinal Screening for Prostate Cancer With Prostate-Specific Antigen
Abstract
OBJECTIVE: To determine for the first 4 years of serial prostate-specific antigen (PSA)-based screening trends in compliance, prevalence of abnormal screening test results, cancer detection rates, and stage and grade of cancers detected. DESIGN: A community-based study of serial screening for prostate cancer with serum PSA measurements. SETTING: University medical center. SUBJECTS: A total of 10 248 male volunteers at least 50 years old who were screened at 6-month intervals for a minimum of 48 months. MAIN OUTCOME MEASURES: The proportion of men who returned for serial screening, the proportion with elevated PSA levels, the proportion with newly elevated PSA levels, prostate cancer detection rates, and the distribution of tumor stages and grades at diagnosis. RESULTS: At 48 months, 79% of volunteers returned for screening. During this interval there was a decrease in the proportion of volunteers with serum PSA levels higher than 4.0 ng/mL (from 10% to 6%-7%), in cancer detection rates (from 3% to <1%), and in the proportion with clinically advanced cancer (from 6% to 2%). In men who underwent surgery, the proportion with high-grade cancer decreased (from 11% to 6%), and the proportion with pathologically advanced cancer was proportionately reduced but not significantly reduced (from 33% to 27%). CONCLUSIONS: With serial PSA-based screening, the proportion of men with abnormal test results decreased, and the prostate cancer detection rate decreased to near the reported population-based incidence rate. There was also a shift to detection of cancers at an earlier clinical stage and detection of lower-grade cancers. If PSA screening is ultimately shown to be beneficial, then appropriate cost-benefit analyses will be required to determine how the shifts in cancer detection rate and cancer stage will affect the economics of serial PSA-based screening.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Catalona, W. J., Partin, A. W., Slawin, K. M., Brawer, M. K., Flanigan, R. C., Patel, A., Richie, J. P., deKernion, J. B., Walsh, P. C., Scardino, P. T., et al. (1998) · JAMA · doi:10.1001/jama.279.19.1542 · Cited by 1,162
PROSTATE SPECIFIC ANTIGEN: A DECADE OF DISCOVERY-WHAT WE HAVE LEARNED AND WHERE WE ARE GOING
POLASCIK, T. J., OESTERLING, J. E., & PARTIN, A. W. (1999) · Journal of Urology · doi:10.1016/s0022-5347(05)68543-6 · Cited by 599
Michalaki, V, Syrigos, K., Charles, P., & Waxman, J. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601814 · Cited by 406
Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force
Harris, R., & Lohr, K. N. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-11-200212030-00014 · Cited by 348
Metadata
- Authors
- Smith, D. S.
- Venue
- JAMA: The Journal of the American Medical Association
- Publisher
- American Medical Association (AMA)
- Published
- 1996-10-23
- Volume
- 276
- Issue
- 16
- Pages
- 1309
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2030353873
- Cited by
- 219
- References
- 0
- FWCI
- 18.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Longitudinal Screening for Prostate Cancer With Prostate-Specific Antigen. https://app.cochat.ai/papers/10.1001/jama.1996.03540160031029
- The paper
- Smith, D. S. (1996). Longitudinal Screening for Prostate Cancer With Prostate-Specific Antigen. JAMA: The Journal of the American Medical Association. https://doi.org/10.1001/jama.1996.03540160031029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.